Acquired by Johnson & Johnson in November 2015, Novira Therapeutics was formerly doing business as Molecmo Nanobiotechnologies, Inc., The firm is an antiviral drug discovery company focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV and HIV infections. Noviraâs oral drugs target the capsid of the virus, and offer a promising treatment option both as monotherapy and in combination with current standards of care. The companyâs antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant viral strains. Novira Therapeutics, Inc. specializes in molecular motor based applications in the fields of nanomedicine, drug discovery, gene therapy, viral treatment, and hybrid bio-sensors. In November 2015 J&J announced agreement to buy Novira Therapeuti
